Sistema de Salut de Catalunya
Institut Català de la Salut
[Swain SM] Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, MedStar Health, Washington, USA. [Macharia H] F. Hoffmann-La Roche Ltd., Basel, Switzerland. [Cortes J] Quirónsalud Group, IOB Institute of Oncology, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Dang C] Department of Medicine, Breast Medicine Service, Memorial Sloan Kettering Cancer Center, New York, USA. [Gianni L] Fondazione Michelangelo, Milano, Italy. [Hurvitz SA] David Geffen School of Medicine, University of California, Los Angeles, USA
Vall d'Hebron Barcelona Hospital Campus
2022-11-28T11:23:56Z
2022-11-28T11:23:56Z
2022-10-15
Early breast cancer; Event-free survival; Pathologic complete response
Cáncer de mama temprano; Supervivencia libre de eventos; Respuesta patológica completa
Càncer de mama precoç; Supervivència lliure d'esdeveniments; Resposta patològica completa
The standard-of-care for patients with pathological complete response (pCR) after neoadjuvant human epidermal growth factor receptor 2 (HER2)-targeted therapy plus chemotherapy is continuation of HER2-targeted therapy in the adjuvant setting. Our objective was to evaluate risk of recurrence or death in these patients and determine if outcomes differed by the HER2-targeted regimen received in each setting. We analyzed patient-level data from five randomized trials evaluating trastuzumab, pertuzumab, or both as part of systemic neoadjuvant and adjuvant therapy for HER2-positive early breast cancer, and assessed event-free survival (EFS) in 1763 patients. Patients with pCR had decreased risk of an EFS event versus those with residual disease (unadjusted hazard ratio [HR] = 0.35; 95% confidence interval [CI]: 0.27–0.46). Regardless of pCR status, after adjusting for baseline factors, reduction in EFS event risk was greater in patients administered pertuzumab/trastuzumab in both settings versus those administered only trastuzumab in both settings (HR = 0.36; 95% CI: 0.26–0.49), or pertuzumab/trastuzumab in the neoadjuvant setting and only trastuzumab in the adjuvant setting (HR = 0.67; 95% CI: 0.47–0.96). Patients with pCR had longer EFS than those with residual disease. Patients treated with pertuzumab/trastuzumab in both the neoadjuvant and adjuvant settings had the lowest risk of breast cancer recurrence.
The analysis was funded by F. Hoffmann-La Roche, Ltd.
Article
Versió publicada
Anglès
Mama - Càncer - Tractament; Quimioteràpia combinada; Anàlisi de supervivència (Biometria); DISEASES::Neoplasms::Neoplasms by Site::Breast Neoplasms; Other subheadings::Other subheadings::Other subheadings::/drug therapy; ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Therapeutics::Drug Therapy::Antineoplastic Protocols::Therapeutics::Drug Therapy::Antineoplastic Combined Chemotherapy Protocols; ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Diagnosis::Prognosis::Treatment Outcome::Disease-Free Survival; ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias de la mama; Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia; TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::terapéutica::farmacoterapia::protocolos antineoplásicos::terapéutica::farmacoterapia::protocolos de quimioterapia antineoplásica combinada; TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::diagnóstico::pronóstico::resultado del tratamiento::supervivencia sin enfermedad
MDPI
Cancers;14(20)
https://doi.org/10.3390/cancers14205051
Attribution 4.0 International
http://creativecommons.org/licenses/by/4.0/
